06:58:24 EDT Thu 25 Apr 2024
Enter Symbol
or Name

Login ID:
Clearmind Medicine Inc
Symbol CMND
Shares Issued 29,225,000
Close 2022-06-07 C$ 0.36
Market Cap C$ 10,521,000
Recent Sedar Documents

Clearmind reviews treatment preclinical results

2022-06-07 10:53 ET - News Release

Dr. Adi Zuloff-Shani reports


Clearmind Medicine Inc. has released positive preclinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

"This exciting research on MEAI could go a long way in helping those who need it," said Dr. Adi Zuloff-Shani, Clearmind's chief executive officer. "While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis."

The preclinical trial, led by Prof. Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI on male Sprague-Dawley rats based on the conditioned place preference (CPP) model.

Rats previously conditioned with cocaine received either cocaine (at 15 milligrams per kilogram (mg/kg)) or MEAI at doses of 2.5, five, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving and that the compound was not itself addictive. The five-milligram-per-kilogram dose was found the most effective dose and selected for further study.

The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.

"Once again, MEAI has shown the potential to become a game changer in the field of addiction treatments," Dr. Zuloff-Shani added. "We intend to further explore the potential of MEAI as an anti-cocaine addiction treatment."

About Clearmind Medicine Inc.

Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.

The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D (research and development) capabilities and discover new candidate treatments for other mental health issues.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.